Paper26106962
Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment.
Wu JT and 3 others. Clinics (Sao Paulo), 2015. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. Papers, record 26106962. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26106962
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antitubercular Agents | Major topic |
| Tuberculosis, Pulmonary | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Bilirubin | |
| Directly Observed Therapy | |
| Drug Administration Schedule | |
| Drug Combinations | |
| Drug Therapy, Combination | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Hyperuricemia | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Radiography | |
| Skin Diseases | |
| Sputum | |
| Treatment Outcome | |
| Vision Disorders |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00979290 | Adverse Reactions and Efficacy of Fixed-dose Combination Anti-tuberculosis (TB) Drugs | Derived from the trial | Yes |
Source ClinicalTrials.gov
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2114029 | [A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment]. | Rev Mal Respir | 1990 | https://conductscience.org/library/papers/2114029 | PubMed |
| 2 | 21239028 | Trends of mycobacterial clinical isolates in Taiwan. | Trans R Soc Trop Med Hyg | 2011 | https://conductscience.org/library/papers/21239028 | PubMed |
| 3 | 324964 | Adverse reactions to rifampicin in antituberculosis regimens. | J Antimicrob Chemother | 1977 | https://conductscience.org/library/papers/324964 | PubMed |
| 4 | 2604291 | Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. | Am Rev Respir Dis | 1989 | https://conductscience.org/library/papers/2604291 | PubMed |
| 5 | 21077990 | Increased prevalence of primary drug-resistant pulmonary tuberculosis in immunocompromised patients. | Respirology | 2011 | https://conductscience.org/library/papers/21077990 | PubMed |
| 6 | 11567729 | Private practitioners and public health: weak links in tuberculosis control. | Lancet | 2001 | https://conductscience.org/library/papers/11567729 | PubMed |
| 7 | 12475151 | Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. | Int J Tuberc Lung Dis | 2002 | https://conductscience.org/library/papers/12475151 | PubMed |
| 8 | 21486974 | Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. | JAMA | 2011 | https://conductscience.org/library/papers/21486974 | PubMed |
| 9 | 12588714 | American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. | Am J Respir Crit Care Med | 2003 | https://conductscience.org/library/papers/12588714 | PubMed |
| 10 | 9562106 | How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. | Int J Tuberc Lung Dis | 1998 | https://conductscience.org/library/papers/9562106 | PubMed |
| 11 | 19460254 | Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. | Int J Tuberc Lung Dis | 2009 | https://conductscience.org/library/papers/19460254 | PubMed |
| 12 | 15182145 | Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. | Int J Tuberc Lung Dis | 2004 | https://conductscience.org/library/papers/15182145 | PubMed |
| 13 | 19251545 | A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. | J Formos Med Assoc | 2009 | https://conductscience.org/library/papers/19251545 | PubMed |
| 14 | 11217670 | The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. | Bull World Health Organ | 2001 | https://conductscience.org/library/papers/11217670 | PubMed |
| 15 | 10091877 | Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. | Int J Tuberc Lung Dis | 1999 | https://conductscience.org/library/papers/10091877 | PubMed |
| 16 | 15599473 | Guidelines for chemotherapy of tuberculosis in Taiwan. | J Microbiol Immunol Infect | 2004 | https://conductscience.org/library/papers/15599473 | PubMed |
| 17 | 23314904 | Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. | Eur Respir J | 2013 | https://conductscience.org/library/papers/23314904 | PubMed |
| 18 | 2648511 | [Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis]. | Rev Mal Respir | 1989 | https://conductscience.org/library/papers/2648511 | PubMed |
| 19 | 20688288 | Drug resistance pattern of mycobacterium tuberculosis complex at a medical center in central Taiwan, 2003-2007. | J Microbiol Immunol Infect | 2010 | https://conductscience.org/library/papers/20688288 | PubMed |
| 20 | 7755232 | Fixed-dose combinations of antituberculous medications to prevent drug resistance. | Ann Intern Med | 1995 | https://conductscience.org/library/papers/7755232 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 32476718 | Health technology assessment of fixed-dose combination regimen in treatment of newly diagnosed smear-positive pulmonary tuberculosis: A meta-analysis. | Med J Armed Forces India | 2020 | https://conductscience.org/library/papers/32476718 | PubMed |
| 30908689 | Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review. | Br J Clin Pharmacol | 2019 | https://conductscience.org/library/papers/30908689 | PubMed |
| 30089476 | Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar. | BMC Infect Dis | 2018 | https://conductscience.org/library/papers/30089476 | PubMed |
| 28538778 | Estimated rates of recurrence, cure, and treatment abandonment in patients with pulmonary tuberculosis treated with a -four-drug fixed-dose combination regimen at a tertiary health care facility in the city of Rio de Janeiro, Brazil. | J Bras Pneumol | 2017 | https://conductscience.org/library/papers/28538778 | PubMed |
| 28152986 | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. | BMC Infect Dis | 2017 | https://conductscience.org/library/papers/28152986 | PubMed |
| 27186634 | Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. | Cochrane Database Syst Rev | 2016 | https://conductscience.org/library/papers/27186634 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26106962
GET https://conductscience.org/api/papers/v1/26106962/references?page=2